Acep Pediatric Drops 80 mg/ml

Acep Pediatric Drops is a paracetamol-based formulation manufactured by Zenith Pharmaceuticals Ltd. Designed for infants and young children, this 80 mg/ml pediatric drops formulation offers rapid relief from fever and mild-to-moderate pain. Priced at ৳30.00 per unit, it provides an affordable solution for managing pediatric discomfort.

This medication effectively treats fever, post-vaccination pain, teething discomfort, headaches, and body aches in children. As part of the non-opioid analgesics class, it inhibits prostaglandin synthesis through COX enzyme pathways while minimizing gastrointestinal side effects compared to NSAIDs.

Dosage guidelines vary by age:

• Below 3 months: 0.5 ml (40 mg) 4 times daily
• 4-11 months: 1 ml (80 mg) every 6 hours
• 1-2 years: 1.5 ml (120 mg) up to 4 times daily

Always use the enclosed dropper and consult a pediatrician for dosing adjustments.

While generally safe, potential side effects include rare skin rashes or allergic reactions. Avoid concurrent use with barbiturates or alcohol due to increased hepatotoxicity risks. Store in original packaging at room temperature, protected from light and moisture.

For alternative formulations, consider pediatric drops from other brands. Zenith Pharmaceuticals ensures strict quality control, making Acep Pediatric Drops a trusted choice for Bangladeshi parents seeking fast-acting fever relief for their children.

0-3 months: 0.5ml (40mg), 4 times daily. 4-11 months: 1ml (80mg). 1-2 years: 1.5ml (120mg). Maintain 4-6 hour intervals between doses. Hepatic/renal impairment requires dose adjustment. Administer directly or mix with food. Avoid prolonged use beyond 3 days without medical supervision.

Side effects of Acep are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.

Pregnancy Category B: Safe in therapeutic doses. Excreted minimally in breast milk (≤0.2% maternal dose). Compatible with lactation at ≤4g/day dosage.

Monitor liver enzymes every 6 months. Alcohol users must not exceed 3g/day. Avoid concurrent paracetamol products. Renal function tests (creatinine clearance) recommended in elderly.

Pediatric: Mandatory physician consultation for <3 months. Geriatric: Reduce dose if CrCl <30ml/min. Hepatic: Limit to 2g/day for Child-Pugh 8-10. Pregnancy: Use cautiously in 2nd trimester.

Liver damage is possible in adults who have taken 10 g or more of Acep. Ingestion of 5 g or more of Acep may lead to liver damage if the patient has following risk factors: If the patient is on long term treatment with Carbamazepine, Phenobarbitone, Phenytoin, Primidone, Rifampicin, St John’s Wort or other drugs that induce liver enzymes, or regularly consumes Ethanol in excess of recommended amounts, or is likely to be Glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms: Symptoms of Acep overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. Immediate treatment is essential in the management of Acep overdose. Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma Acep concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of Acep. However, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral Methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should be discussed with the NPIS or a liver unit.